The intercellular communication mediated by extracellular vesicles (EVs) has gained international interest during the last decade. Interfering with the mechanisms regulating this cellular process might find application particularly in oncology where cancer cell-derived EVs play a role in tumour microenvironment transformation. Although several mechanisms were ascribed to explain the internalization of EVs, little is our knowledge about the fate of their cargos, which are crucial to mediate their function.
bud from microvilli and/or cilia. 13, 14 Once released into the extracellular milieu, the uptake of EVs by recipient cells can be accomplished by several molecular mechanisms of internalization, which are not mutually exclusive, [15] [16] [17] [18] such as clathrin-mediated endocytosis 17 or lipid raft-dependent endocytosis. 19 In spite of this knowledge, fundamental questions remain about the fate of endocytosed EVs particularly their biological cargo, which is crucial for their function. 20 Our groups are studying EVs released by stem cells and cancerous cells, notably melanoma cells. We have extensively characterized those secreted by metastatic FEMX-I cells. Electron microscopy examination has revealed the presence of a mixture of small and large EVs, suggesting that exosomes and ectosomes are simultaneously produced. 21 The proteomic analysis of EVs, particularly those harbouring the stem (cancer stem) cell marker CD133, 22 has defined their contents. They are particularly rich in tetraspanin proteins (CD9, CD63 and CD81) and in pro-metastatic proteins, notably CD44, MAPK4K, ADAM10 and Annexin A2. Importin β1, a protein mediating nuclear transportation of cytoplasmic proteins through the nuclear pore complex, was also found therein. By monitoring the internalization of melanoma-derived EVs and the intracellular routes of their content, particularly CD9 (see below), we discovered that EV-associated proteins are transported into the nucleus of the host cell through late endosomes entering the nucleoplasmic reticulum ( Figure 1A ). 23 Therein, EV-associated cargo molecules can modify the gene expression of the host cells. These surprising findings are in line with numerous studies showing the atypical nuclear localization of the EV-associated proteins CD9 and CD133 as well as the shuttling of proteins and nucleic acids to nucleoplasm of recipient cells. 3, [24] [25] [26] [27] [28] Recently, we described that two proteins, ie vesicle-associated membrane protein-associated protein A (VAP-A) and the cytoplasmic oxysterol-binding protein-related protein 3 (ORP3), are essential for the entry and the tethering of late endosomes to nuclear envelope invaginations of type II ( Figure 1B ). They form a tripartite complex with late endosome-associated Rab7 proteins. 29 Silencing VAP-A or ORP3 abrogated the association of Rab7-positive late endosomes with nuclear envelope invaginations, hence the transport of internalized EV-derived cargo molecules to the nucleoplasm of recipient cells. 29 The nuclear pores play a role in these processes given the treatment with importazole, a small molecule inhibitor of importin-β-mediated nuclear import, impaired the nuclear transfer of EV-derived proteins. 23 Finally, the initial internalization of CD9 + EVs occurs by endocytosis, which is an essential step for the nuclear localization of EV-associated materials, given dynasore and methyl-β-cyclodextrin, two compounds known to inhibit the endocytosis mediated by clathrin/dynamin and lipid raft respectively, abrogated it.
23
CD9 (alias Tetraspanin-29, motility-related protein-1) is an integral membrane protein that is physiologically involved in cell fusion, adhesion and motility. [30] [31] [32] For instance, CD9 has an important role in muscle cell fusion and in canine distemper virus and HIV-1-induced cell-cell fusion. [33] [34] [35] Depending on the context, CD9 functions have a metastasis suppressor or promoter activity (reviewed in Ref. 36 ).
CD9 has been extensively studied as a potential therapeutic target.
Anti-CD9 monoclonal antibodies (Ab) were found to specifically inhibit the trans-endothelial migration of melanoma cells. 37 We have
shown that anti-CD9, but not anti-CD133, Ab enhances the nuclear uptake of EVs in recipient cells ( Figure 1C) . 23 This effect is greater in melanoma cells than in mesenchymal stromal cells (MSCs), presumably because of the higher expression level of CD9 in cancer cells in comparison to stromal cells. Moreover, silencing CD9 in EVs and/or recipient cells strongly decreased the endocytosis of EVs and abolished the nuclear transfer of their contents, even in the presence of the anti-CD9 Ab ( Figure 1C ). 23 Here, we designed a strategy to block the uptake of EVs and the nuclear translocation of their cargos by recipient cells. To that aim, we generated an antigen-binding fragment (Fab fragment; hereafter CD9 Fab) from 5H9 anti-CD9 Ab (CD9 Ab), which could potentially saturate CD9 molecules present at the cell surface of host cells and EV-associated ones and hence impair their function. 38 The Ab and Fab fragment derived therefrom have been successfully employed for the treatment of different types of cancer, mainly through the inhibition of cell surface receptors. 39 We report that monovalent CD9 Fab at doses achievable in vivo 
| ME THODS

| Cell culture
The FEMX-I cell line was originally derived from the lymph node metastasis of a patient with malignant melanoma. 41 FEMX-I cells were highly metastatic in immunodeficient mice. 41, 42 They were found to be wild-type for BRAF, PTEN and NRAS. 23, 29 The human A375 melanoma cell line was obtained from the American Type Culture Collection (catalog number #CRL-1619 ™ ), whereas the human C8161 melanoma cell line was obtained from G. Pizzorno (University of Tennessee College of Medicine, Chattanooga, TN). 43, 44 All cell lines were cultured in RPMI-1640 (#10-041-CV; Corning Inc., Corning, NY) containing 10%
foetal bovine serum (FBS; Atlanta Biologicals Inc., Flowery Branch, GA), 2 mmol/L l-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Corning Inc.). Cells were used between passages 3 and 15.
Cell lines were authenticated by morphology, proteomics and gene expression analysis as described. 45 They were regularly tested for mycoplasma contamination using Venor ™ GeM mycoplasma detection kit (Sigma-Aldrich, St. Louis, MO).
Human bone marrow-derived MSCs, isolated from bone marrow aspirates from normal adult donors after obtaining informed consent as described, 46 were obtained from Dr. D. J. Prockop (Texas A&M) and prepared under a protocol approved by the Texas A&M Institutional Review Board. MSCs were used between passages 2 and 5. Their multipotency was regularly monitored by their differentiation into adipocytes and osteoblasts. 47 MSCs and FEMX-I cells expressing ectopically CD9-green fluorescent protein (GFP) fusion protein were established as described. 23 Under these conditions, almost all cells are positive. They were used to produce fluorescent EVs (see below).
FEMX-I cells depleted of CD9 by means of CD9 shRNA lentiviral particles were previously described. 23 Approximately 85% of infected cells showed no CD9 expression (data not shown).
| Production of CD9 antibody Fab fragment
Culture of 5H9 hybridoma cells 38 and the production of CD9 Ab were performed at Mayo Clinic (Antibody Hybridoma Core, Rochester, MN). PBS and the protein concentration was determined by measuring absorbance at 280 nm. Aliquots of the antibody (1 mg/mL) were stored at −80°C without addition of sodium azide.
The Fab fragment was generated using the Pierce Fab Purification kit (#44985; Thermo Fisher Scientific). Briefly, the CD9 Ab (500 μg)
was incubated with papain immobilized on agarose resin for 3 hours at 37°C. The digested antibody was collected by centrifugation (5000 g, 
| SDS-PAGE and immunoblotting
Preparation of Fab fragments was assessed using SDS-PAGE under non-reduced or reduced (ie in the presence of β-mercaptoetha- 
| Confocal laser scanning microscopy and fluorescence quantification
Cell surface immunolabelling of native or CD9-depleted FEMX-I cells was performed as described. 48 Briefly, cells growing on fibronectin-coated coverslips were washed with ice-cold PBS con- Alternatively, cells incubated with CD9-GFP + EVs (see above)
were fixed in 4% PFA and afterward permeabilized with 0.2% Tween 20 diluted in PBS (permeabilization buffer). Both steps F I G U R E 1 Entry and delivery of extracellular vesicles (EV)-derived cargo molecules into the nucleoplasm of recipient cells. A, Two major steps were proposed to explain the delivery of EV-associated molecules to the nuclear compartment of recipient cells. First, the EVs are internalized by endocytosis at the plasma membrane (i). Second, once inside the endocytic pathway, a fraction of late endosomes (LE) penetrates the type II nuclear envelope invaginations where their content, notably the endocytosed EV-associated molecules, are transferred into the nucleoplasm (ii). Two types of nuclear envelope invaginations are described. Type I invaginations (I) are those in which solely the inner nuclear membrane (INM) penetrates into the nucleoplasm, whereas type II invaginations (II) involve both the outer nuclear membrane (ONM) and INM. The endoplasmic reticulum (ER) is a continuation of ONM. B, Key players involved in the translocation of Rab7 + late endosomes to nuclear envelope invagination. Two proteins, vesicle-associated membrane protein-associated protein A (VAP-A) and the cytoplasmic oxysterol-binding protein-related protein 3 (ORP3) forming a tripartite complex with late endosome-associated Rab7 protein, are indispensable for the entry of late endosomes to the nuclear envelope invagination and/or their tether to ONM (I). Nuclear pores are somehow involved in the translocation of EV-associated soluble (II) and membranous (III) cargo molecules into the nucleus. It remains to be explained how membranous components of EVs are extracted from the late endosomal membrane upon fusion of the former with the latter and the transport mechanism through nuclear pores, which are size restricted. C, Silencing CD9 in recipient cells and/or EVs or both interferes with the endocytosis of EVs and the nuclear transfer of their cargo molecules. Although the presence of divalent CD9 Ab stimulated these events with native cells and EVs, the lack of CD9 abrogated them. 23 Panels A and B were modified from Ref.
were performed for 15 minutes at RT. They were then incubated in blocking buffer III (PBS containing 1% BSA) and labelled with mouse 
| Statistical analysis
All experiments were performed at least in triplicate. A minimum 
| RE SULTS
| Generation of CD9 antibody Fab fragment
Given the positive impact of divalent Ab directed against CD9 on the uptake of CD9 + EVs by melanoma cells and the negative impact upon silencing CD9 on either EVs or recipient cells, 23 we sought whether CD9 Fab could influence the internalization and consequently the intercellular transfer of EV-associated cargo molecules. To investigate this issue, we generated CD9 Fab from 5H9 Ab, which recognizes an unidentified epitope in the extracellular part of CD9 ( Figure S1A ). 38 The Ab (IgG 1 kappa) produced from hybridoma clone 5H9 was digested with papain to generate the Fab and Fc fragments. The latter were removed selectively using immobilized protein A ( Figure S1B ). As observed using SDS-PAGE under non-reducing and reducing conditions, the 5H9 Ab was successfully digested and the 50-kDa CD9 Fab was isolated ( Figure S1C ).
| Characterization of CD9 Fab
To determine the functionality of CD9 Fab, we evaluated its bind- that it could specifically label the cell surface CD9 molecules. We concluded that the monovalent CD9 Fab could be useful in achieving our objective, ie interfering with the uptake of CD9 + EVs.
| Differential effect of CD9 Fab versus native antibody on the internalization of EVs
To determine the impact of CD9 Fab on the internalization of EVs by melanoma cells, we used engineered FEMX-I cells to express the CD9-GFP fusion protein. 23 These cells release in vivo-labelled fluorescent EVs that could be used to monitor EV uptake upon incuba- 
| CD9 Fab inhibits the nuclear transfer of EVderived cargo proteins
We previously reported that cargo proteins derived from EVs are not only internalized by host cells, but also a fraction of them is Figure 3A , section, green circle; 3C; see also Table 1) . As previously demonstrated, 23, 29 CD9-GFP + signal in the nuclear compartment appeared with a punctate pattern ( Figure 3A ; Figure S2B , green circle).
The addition of different amounts of CD9-GFP + EVs (eg, 5.0 × 10 7 or 1.0 × 10 9 particle per mL) was also evaluated in FEMX-I cells. In most cases, the numbers of nuclear CD9-GFP were significantly lower or higher in cells exposed to CD9 Fab or CD9 Ab respectively ( Figure 3C ).
Only with a high amount of EVs (ie 1.0 × 10 9 particle per mL) no 
| A minimal concentration of CD9 Fab is necessary to interfere with EV uptake
We assessed whether the uptake of EVs is dependent on the concentration of CD9 Fab. FEMX-I cells were subjected to increasing concentrations of CD9 Fab or CD9 Ab prior to incubation with CD9-GFP + EVs (2.5 × 10 8 particle per mL). As shown in Figure 5A , the uptake of EVs was progressively inhibited as the concentration of CD9
Fab increased, whereas the opposite effect was again observed in cells treated with CD9 Ab, ie more EVs were internalized with increasing CD9 Ab concentration. A similar trend was observed in the number of CD9-GFP signals in the nuclear compartment ( Figure 5B ).
These results are in line with the interference of CD9 Fab to cell surface CD9 Ab binding observed using flow cytometry ( Figure 2E ).
Thus, a minimal amount of antibody (ie 25 μg/mL) seems to be indispensable to inhibit (or promote) the EV uptake.
Lastly, we determined whether the pre-incubation of EVs with Ab (25 μg/mL) or of both EVs and cells individually, instead of cells Similarly, we wished to exclude that the addition of Abs, particularly CD9 Ab, to EVs would reduce their internalization by favouring, for instance, their clustering. As presented in Table 1 , we found that the pre-incubation of cells with Abs did not influence the final outcome when compared to the pre-incubation of EVs (procedure A vs. B).
However, the nuclear localization of EV-derived cargo proteins was significantly reduced when both entities (EVs and cells) were pre-incubated individually with the monovalent, but not the divalent, Ab (see procedure C by comparison to A).
| D ISCUSS I ON
In this study, we demonstrated that a monovalent Ab directed against properties driven by CD9. 51 In such process, CD9 might organize the components (proteins and lipids) of plasma membrane and/or EV membrane into a specific tetraspanin web ( Figure 6B , green), whose constituents (eg, adhesion proteins) would somehow regulate the interaction with EVs and promote their endocytosis. [52] [53] [54] [55] Similarly, CD9
has been proposed to act as a scaffold in the regulation of adhesion molecules at the immune synapse and T lymphocyte activation. 56 It remains to be determined whether the cis-dimerization of CD9 in the membrane of recipient cells as well as in EVs is involved. 57 We could not exclude that a trans-dimerization of CD9, ie molecules expressed in opposite membranes, occurs. Indeed, our present data with divalent Ab as mentioned above and the complete lack of EV endocytosis previously observed in melanoma cells in which CD9 was silenced in both entities (cells and/or EVs), suggest it ( Figure 1C) . 23 (A, B) CD9 Fab will saturate CD9 proteins present at the surface of cells and EVs, hence interfere with its CD9 function. CD9 Fab can impede the cis/trans-dimerization of CD9, its oligomerization and/or its interaction with other protein partners and block EV endocytosis (red bar). In contrast, divalent CD9 Ab could cross-link CD9 proteins associated with host cells and EVs and consequently stimulate the endocytosis on EVs (green arrow). In the latter case, cis-dimerization/oligomerization of CD9 might organize the components (proteins and lipids) of plasma membrane and/or EV membrane into a specific tetraspanin web (green segment), whose constituents, notably potential adhesion proteins as illustrated would somehow regulate the cell-EV interaction and promote the endocytosis of EVs amyotrophic lateral sclerosis), could benefit from this new potential therapeutic approach. 62, 63 Finally, our observations could benefit the areas of regenerative medicine and tissue engineering. Here, the stimulation of EV endocytosis by specific divalent antibodies could favour tissue/organ repair. 64 Myocardial regeneration might be a good example for such intervention with MSCs as a promising source of donor cell EVs. 65, 66 Such approach could be an interesting alternative to stem cell-based therapy.
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